Cargando…
Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study
INTRODUCTION: Understanding the human immune response to Plasmodium falciparum gametocytes and its association with gametocytemia is essential for understanding the transmission of malaria as well as progressing transmission blocking vaccine candidates. METHODS: In a multi-national clinical efficacy...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022117/ https://www.ncbi.nlm.nih.gov/pubmed/35463638 http://dx.doi.org/10.3389/fcimb.2022.804470 |
_version_ | 1784690013313695744 |
---|---|
author | O’Flaherty, Katherine Chan, Jo-Anne Cutts, Julia C. Zaloumis, Sophie G. Ashley, Elizabeth A. Phyo, Aung Pyae Drew, Damien R. Dondorp, Arjen M. Day, Nicholas P. Dhorda, Mehul Fairhurst, Rick M. Lim, Pharath Amaratunga, Chanaki Pukrittayakamee, Sasithon Hien, Tran Tinh Htut, Ye Mayxay, Mayfong Faiz, M. Abul Mokuolu, Olugbenga A. Onyamboko, Marie A. Fanello, Caterina Takashima, Eizo Tsuboi, Takafumi Theisen, Michael Nosten, Francois Beeson, James G. Simpson, Julie A. White, Nicholas J. Fowkes, Freya J. I. |
author_facet | O’Flaherty, Katherine Chan, Jo-Anne Cutts, Julia C. Zaloumis, Sophie G. Ashley, Elizabeth A. Phyo, Aung Pyae Drew, Damien R. Dondorp, Arjen M. Day, Nicholas P. Dhorda, Mehul Fairhurst, Rick M. Lim, Pharath Amaratunga, Chanaki Pukrittayakamee, Sasithon Hien, Tran Tinh Htut, Ye Mayxay, Mayfong Faiz, M. Abul Mokuolu, Olugbenga A. Onyamboko, Marie A. Fanello, Caterina Takashima, Eizo Tsuboi, Takafumi Theisen, Michael Nosten, Francois Beeson, James G. Simpson, Julie A. White, Nicholas J. Fowkes, Freya J. I. |
author_sort | O’Flaherty, Katherine |
collection | PubMed |
description | INTRODUCTION: Understanding the human immune response to Plasmodium falciparum gametocytes and its association with gametocytemia is essential for understanding the transmission of malaria as well as progressing transmission blocking vaccine candidates. METHODS: In a multi-national clinical efficacy trial of artemisinin therapies (13 sites of varying transmission over South-East Asia and Africa), we measured Immunoglobulin G (IgG) responses to recombinant P. falciparum gametocyte antigens expressed on the gametocyte plasma membrane and leading transmission blocking vaccine candidates Pfs230 (Pfs230c and Pfs230D1M) and Pfs48/45 at enrolment in 1,114 participants with clinical falciparum malaria. Mixed effects linear and logistic regression were used to determine the association between gametocyte measures (gametocytemia and gametocyte density) and antibody outcomes at enrolment. RESULTS: Microscopy detectable gametocytemia was observed in 11% (127/1,114) of participants at enrolment, and an additional 9% (95/1,114) over the follow-up period (up to day 42) (total 20% of participants [222/1,114]). IgG levels in response to Pfs230c, Pfs48/45 and Pfs230D1M varied across study sites at enrolment (p < 0.001), as did IgG seroprevalence for anti-Pfs230c and D1M IgG (p < 0.001), but not for anti-Pfs48/45 IgG (p = 0.159). In adjusted analyses, microscopy detectable gametocytemia at enrolment was associated with an increase in the odds of IgG seropositivity to the three gametocyte antigens (Pfs230c OR [95% CI], p: 1.70 [1.10, 2.62], 0.017; Pfs48/45: 1.45 [0.85, 2.46], 0.174; Pfs230D1M: 1.70 [1.03, 2.80], 0.037), as was higher gametocyte density at enrolment (per two-fold change in gametocyte density Pfs230c OR [95% CI], p: 1.09 [1.02, 1.17], 0.008; Pfs48/45: 1.05 [0.98, 1.13], 0.185; Pfs230D1M: 1.07 [0.99, 1.14], 0.071). CONCLUSION: Pfs230 and Pfs48/45 antibodies are naturally immunogenic targets associated with patent gametocytemia and increasing gametocyte density across multiple malaria endemic settings, including regions with emerging artemisinin-resistant P. falciparum. |
format | Online Article Text |
id | pubmed-9022117 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90221172022-04-22 Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study O’Flaherty, Katherine Chan, Jo-Anne Cutts, Julia C. Zaloumis, Sophie G. Ashley, Elizabeth A. Phyo, Aung Pyae Drew, Damien R. Dondorp, Arjen M. Day, Nicholas P. Dhorda, Mehul Fairhurst, Rick M. Lim, Pharath Amaratunga, Chanaki Pukrittayakamee, Sasithon Hien, Tran Tinh Htut, Ye Mayxay, Mayfong Faiz, M. Abul Mokuolu, Olugbenga A. Onyamboko, Marie A. Fanello, Caterina Takashima, Eizo Tsuboi, Takafumi Theisen, Michael Nosten, Francois Beeson, James G. Simpson, Julie A. White, Nicholas J. Fowkes, Freya J. I. Front Cell Infect Microbiol Cellular and Infection Microbiology INTRODUCTION: Understanding the human immune response to Plasmodium falciparum gametocytes and its association with gametocytemia is essential for understanding the transmission of malaria as well as progressing transmission blocking vaccine candidates. METHODS: In a multi-national clinical efficacy trial of artemisinin therapies (13 sites of varying transmission over South-East Asia and Africa), we measured Immunoglobulin G (IgG) responses to recombinant P. falciparum gametocyte antigens expressed on the gametocyte plasma membrane and leading transmission blocking vaccine candidates Pfs230 (Pfs230c and Pfs230D1M) and Pfs48/45 at enrolment in 1,114 participants with clinical falciparum malaria. Mixed effects linear and logistic regression were used to determine the association between gametocyte measures (gametocytemia and gametocyte density) and antibody outcomes at enrolment. RESULTS: Microscopy detectable gametocytemia was observed in 11% (127/1,114) of participants at enrolment, and an additional 9% (95/1,114) over the follow-up period (up to day 42) (total 20% of participants [222/1,114]). IgG levels in response to Pfs230c, Pfs48/45 and Pfs230D1M varied across study sites at enrolment (p < 0.001), as did IgG seroprevalence for anti-Pfs230c and D1M IgG (p < 0.001), but not for anti-Pfs48/45 IgG (p = 0.159). In adjusted analyses, microscopy detectable gametocytemia at enrolment was associated with an increase in the odds of IgG seropositivity to the three gametocyte antigens (Pfs230c OR [95% CI], p: 1.70 [1.10, 2.62], 0.017; Pfs48/45: 1.45 [0.85, 2.46], 0.174; Pfs230D1M: 1.70 [1.03, 2.80], 0.037), as was higher gametocyte density at enrolment (per two-fold change in gametocyte density Pfs230c OR [95% CI], p: 1.09 [1.02, 1.17], 0.008; Pfs48/45: 1.05 [0.98, 1.13], 0.185; Pfs230D1M: 1.07 [0.99, 1.14], 0.071). CONCLUSION: Pfs230 and Pfs48/45 antibodies are naturally immunogenic targets associated with patent gametocytemia and increasing gametocyte density across multiple malaria endemic settings, including regions with emerging artemisinin-resistant P. falciparum. Frontiers Media S.A. 2022-04-07 /pmc/articles/PMC9022117/ /pubmed/35463638 http://dx.doi.org/10.3389/fcimb.2022.804470 Text en Copyright © 2022 O’Flaherty, Chan, Cutts, Zaloumis, Ashley, Phyo, Drew, Dondorp, Day, Dhorda, Fairhurst, Lim, Amaratunga, Pukrittayakamee, Hien, Htut, Mayxay, Faiz, Mokuolu, Onyamboko, Fanello, Takashima, Tsuboi, Theisen, Nosten, Beeson, Simpson, White and Fowkes https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology O’Flaherty, Katherine Chan, Jo-Anne Cutts, Julia C. Zaloumis, Sophie G. Ashley, Elizabeth A. Phyo, Aung Pyae Drew, Damien R. Dondorp, Arjen M. Day, Nicholas P. Dhorda, Mehul Fairhurst, Rick M. Lim, Pharath Amaratunga, Chanaki Pukrittayakamee, Sasithon Hien, Tran Tinh Htut, Ye Mayxay, Mayfong Faiz, M. Abul Mokuolu, Olugbenga A. Onyamboko, Marie A. Fanello, Caterina Takashima, Eizo Tsuboi, Takafumi Theisen, Michael Nosten, Francois Beeson, James G. Simpson, Julie A. White, Nicholas J. Fowkes, Freya J. I. Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study |
title | Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study |
title_full | Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study |
title_fullStr | Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study |
title_full_unstemmed | Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study |
title_short | Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study |
title_sort | anti-gametocyte antigen humoral immunity and gametocytemia during treatment of uncomplicated falciparum malaria: a multi-national study |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022117/ https://www.ncbi.nlm.nih.gov/pubmed/35463638 http://dx.doi.org/10.3389/fcimb.2022.804470 |
work_keys_str_mv | AT oflahertykatherine antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT chanjoanne antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT cuttsjuliac antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT zaloumissophieg antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT ashleyelizabetha antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT phyoaungpyae antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT drewdamienr antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT dondorparjenm antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT daynicholasp antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT dhordamehul antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT fairhurstrickm antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT limpharath antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT amaratungachanaki antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT pukrittayakameesasithon antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT hientrantinh antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT htutye antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT mayxaymayfong antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT faizmabul antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT mokuoluolugbengaa antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT onyambokomariea antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT fanellocaterina antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT takashimaeizo antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT tsuboitakafumi antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT theisenmichael antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT nostenfrancois antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT beesonjamesg antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT simpsonjuliea antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT whitenicholasj antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy AT fowkesfreyaji antigametocyteantigenhumoralimmunityandgametocytemiaduringtreatmentofuncomplicatedfalciparummalariaamultinationalstudy |